ClinicalTrials.gg
RecruitingNCT06101758SARCOLIVERUpdated Oct 26, 2023

Ultrasound Assessment of Sarcopenia in Patients With Chronic Liver Disease: the SARCOLIVER Study

An interventional study of Handgrip strength test and total body Dual Energy X-Ray Absorptiometry (DXA) in Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2023-10-26.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Not applicable
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Liver Cirrhosis with a site in Italy — 22 open to participants now, 27 under way, 3 of them phase 3. Liver Cirrhosis · Italy.

Planned enrollment
19th of 46
125 · median 105
Started
2023
with 8 others
No phase
12 of 78
5 open now
Primary completion
2024-07
later than 2 of 26 live
Registered
58th of 78
by date
Lead sponsor
8 of 78
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Among the 78 studies in Liver Cirrhosis with a site in Italy, this one is the 19th largest by planned enrollment of the 46 interventional ones that give a count, is one of 9 that started in 2023, is one of 12 with no phase, reaches primary completion later than 2 of the 26 other live ones, and was the 58th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

22 of the 78 studies in Liver Cirrhosis with a site in Italy are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Liver Cirrhosis with a site in Italy, or all of them as a file.
02

Study summary

Sarcopenia is a complex multifactorial syndrome which could be present in older age (primary sarcopenia) or earlier in chronic disease (secondary sarcopenia). Even if in patients with chronic liver disease an association among sarcopenia and poor clinical outcomes is well known, the data available about the prevalence of sarcopenia in patients with liver cirrhosis, non-alcoholic fatty liver disease and hepatocellular carcinoma are very variable according to the populations in object and, furthermore, few data are available regarding the use of muscular ultrasound to detect this condition. The aim of this study is to define the prevalence of sarcopenia in patients with liver cirrhosis, non-alcoholic fatty liver disease and hepatocellular carcinoma in follow-up at our center and the clinical outcomes associated with this condition, and to determine the reliability of muscular ultrasound to diagnose the condition of sarcopenia through a comparison with other validated techniques such as computed tomography, magnetic resonance imaging and dual-energy X-ray absorptiometry.

03

Conditions studied

  • Liver Cirrhosis
  • Non-Alcoholic Fatty Liver Disease
  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to express
  • Diagnosis of liver cirrhosis or non-alcoholic fatty liver disease or hepatocellular carcinoma based on clinical characteristics, biochemical serum tests and liver imaging examination or liver histologic examination if available

Exclusion criteria

Exclusion Criteria:

  • inability to express
  • pregnancy
  • presence of a concomitant oncologic disease different from hepatocellular carcinoma
  • presence of a concomitant gastrointestinal disease able to influence the absorption and digestion of nutrients (e.g. inflammatory bowel disease, celiac disease, short-bowel syndrome, congenital defects of metabolism)
  • presence of a concomitant gastrointestinal or neurologic disease able to influence the ability of feeding (e.g. dysphagia, parkinson disease, neuromuscular diseases, diseases of the autonomic nervous system, cognitive impairment or dementia)
  • chronic kidney disease from stage 3 B (IIIB) according to Kidney Disease: Improving Global Outcomes (KDIGO) classification ( \<45ml/min/1.73m2)
  • chronic heart failure from stage Ney York Heart Association () II
  • concomitant infection from Mycobacterium Tuberculosis or or chronic parasitic infections
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
125 participants (estimated)

Study arms

  • Experimental
    Muscular ultrasound assessment

    Adult patients aged 18-69 years with a diagnosis of either liver cirrhosis, non-alcoholic fatty liver disease or hepatocellular carcinoma

    Diagnostic Test: Handgrip strength test · Diagnostic Test: total body Dual Energy X-Ray Absorptiometry (DXA) · Diagnostic Test: Muscle ultrasound

Interventions

  • Diagnostic testHandgrip strength test

    A handgrip strength test using a hydraulic hand dynamometer will be performed

  • Diagnostic testtotal body Dual Energy X-Ray Absorptiometry (DXA)

    A total body Dual Energy X-Ray Absorptiometry (DXA) to estimate muscle mass will be performed

  • Diagnostic testMuscle ultrasound

    A muscular ultrasound of abdominal muscles, forearm muscles, quadriceps and gastrocnemius will be performed

06

What researchers measure

Primary outcomes

  1. To calculate the prevalence of the condition of sarcopenia in patients with liver cirrhosis, non-alcoholic fatty liver disease and hepatocellular carcinoma

    Time frame: 24 months

Secondary outcomes

  1. Association among sarcopenia and survival or acute decompensation events in patients with liver cirrhosis

    Time frame: 24 months

  2. To calculate the prevalence of obesity with sarcopenia in patients with non-alcoholic fatty liver disease

    Time frame: 24 months

  3. To evaluate the association among sarcopenia and therapeutic response in patients with hepatocellular carcinoma

    Time frame: 24 months

  4. To calculate cohen's Kappa to evaluate the concordance among muscular ultrasound and dual-energy X-ray absorption, computed tomography scan and magnetic resonance imaging in the detection of sarcopenia

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
  • CEMAD
    Roma, RM 00168, Italy
    Recruiting
    • Maria Assunta Zocco · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Jul 2024, 9 months after the start.

Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 9 months is below that.

Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2023
First posted
Oct 26, 2023
StartActual
Oct 20, 2023
Primary completionEst.
Jul 2024
CompletionEst.
Jul 2025
Last update
Oct 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06101758
Responsible party
Zocco Maria Assunta (Prof, Fondazione Policlinico Universitario Agostino Gemelli IRCCS) — Principal investigator
First posted
Oct 26, 2023
Start date
Oct 20, 2023
Primary completion
Jul 2024 (estimated)
Completion
Jul 2025 (estimated)
Last update
Oct 26, 2023

Study contacts

Maria Assunta Zocco
Contact
Mariaassunta.zocco@policlinicogemelli.it
063015 1

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion